Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015)

Abstract

Activities of tedizolid and comparators were evaluated against gram-positive isolates responsible for skin and skin structure infections, pneumonia, and bloodstream infections. Non-duplicate gram-positive isolates (8011) were collected from 20 European countries/regions.

Tedizolid (0.12 mg/L) showed similar results of minimum inhibitory concentration required to inhibit the growth of 50% of organisms (MIC₅₀) regardless of pathogen/group or infection type, except for coagulase-negative staphylococci, Enterococcus faecalis, and viridans group streptococci (VGS), against which tedizolid had MIC₅₀ values of 0.06, 0.25, and 0.06 mg/L, respectively. Similar results of tedizolid MIC₅₀ and minimum inhibitory concentration required to inhibit the growth of 90% of organisms (MIC₉₀) (MIC_50/90, 0.12/0.12 mg/L) were obtained against methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Tedizolid, linezolid, and daptomycin were active against enterococci. Tedizolid (MIC₉₀, 0.12–0.25 mg/L), ceftaroline (MIC₉₀, 0.12 mg/L), and vancomycin (MIC₉₀, 0.25–0.5 mg/L) had the lowest MIC₉₀ values against Streptococcus pneumoniae and VGS, whereas ceftaroline (MIC₉₀, ≤0.015 mg/L), penicillin (MIC₉₀, ≤0.06 mg/L), ceftriaxone (MIC₉₀, ≤0.06–0.12 mg/L), and tedizolid (MIC₉₀, 0.12 mg/L) were the most potent against β-haemolytic streptococci.

Tedizolid displayed potent activity against gram-positive isolates from Europe, regardless of infection type.

Keywords:

• Oxazolidinones
• Linezolid
• MRSA
• VRE
• Disease
• Surveillance

Acknowledgements

The authors wish to thank the following staff members at JMI Laboratories: L.R. Duncan, M. Janechek, M.D. Huband, J. Oberholser, P.R. Rhomberg, J. Schuchert, J.M. Streit, and L.N. Woosley for technical support.

Disclosure statement

This study was performed by JMI Laboratories and supported by Merck Sharp & Dohme Corp., which included funding for services related to preparing this manuscript.

Data availability

This is an original work and data set repository and published article in which the data set was originally described have not been previously published. Upon request and subject to certain criteria, conditions, and exceptions, JMI Laboratories and Merck & Co., Inc. will provide access to the databases utilized here. Data may be requested 12 months after study publication. Data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with JMI Laboratories and Merck & Co., Inc.

Notes on contributors

Dr. Michael A. Pfaller is a Director/Consultant at JMI Laboratories. Dr. Pfaller’s academic and research interests include molecular epidemiology of nosocomial fungal infections, antifungal therapy, and antifungal susceptibility testing, as well as the diagnosis and control of nosocomial infections.

Dr. Helio S. Sader joined JMI Laboratories in 2003 and has primarily worked on national and global antimicrobial surveillance programs and new drug development. He is responsible for designing and overseeing antimicrobial surveillance studies and new drug development projects. His work encompasses scientific research, data analysis and medical writing. Dr. Sader is also responsible for the preparation of abstracts/poster for scientific meetings and manuscripts for submission to peer-reviewed journals. Dr. Sader has authored more than 400 peer-reviewed articles and 25 book chapters.

Dr. Dee Shortridge is a Senior Director for Antimicrobial Development at JMI Laboratories. In her current position, Dr. Shortridge is responsible for overseeing new antibiotic development projects including diagnostic device development, surveillance projects and clinical trial studies.

Dr. Mariana Castanheira is responsible for designing and overseeing antimicrobial and antifungal drug development projects, surveillance studies, and molecular projects that characterize resistance mechanisms. Dr. Castanheira is the leading author for over 200 publications and numerous conference presentations.

Dr. Robert K. Flamm is the Chief Scientific Officer at JMI Laboratories. In his current position, he has scientific oversight of protocol designs, standard operating procedures and associated analyses, reports, and publications. This includes development programs/protocols, clinical trials, pathogen identification, and drug resistance detection (phenotypic/molecular). He has authored or coauthored more than 125 publications and 200 presentations at national and international meetings.

Dr. Rodrigo Mendes is a Director for Molecular and Microbiology at JMI Laboratories. In his current position, he is responsible for planning, designing and overseeing microbiology projects related to antimicrobial drug development and surveillance for bacterial drug resistance. Moreover, Dr. Mendes has been involved in molecular studies for further characterization of Gram-negative and -positive organisms and in investigations of resistance mechanisms and epidemiology typing. Dr. Mendes is the leading author for over 200 peer-reviewed scientific publications and conference presentations.

Additional information

Funding

Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.